Catalog No.
Product Name
Application
Product Information
Citations
-
Stable Isotope
Lidocaine-d10 hydrochloride is a deuterium-labeled analog of Lidocaine hydrochloride, primarily functioning as a stable isotope. It inhibits sodium channels through complex voltage and use dependence, making it significant in studies of neuronal activity. Additionally, it reduces growth, migration, and invasion of gastric carcinoma cells by up-regulating miR-145 expression and inactivating the MEK/ERK and NF-κB signaling pathways. This compound is valuable for research into ventricular arrhythmia and broader cardiovascular studies. -
Antibiotic
Quinocetone is an orally active antibiotic that targets various pathogenic microorganisms, making it effective as an animal feed additive to enhance meat production in livestock and poultry. It demonstrates antibacterial activity while also exhibiting tissue-specific toxicity, notably in the liver and lymphocytes. Quinocetone induces autophagy through the ATF6/DAPK1 pathway and activates the NF-κB and iNOS pathways, resulting in cell apoptosis and hepatocyte vacuolar degeneration. Furthermore, it can inhibit the Nrf2/HO-1 pathway and promote the production of reactive oxygen species (ROS), contributing to oxidative stress and DNA damage. -
Nrf2 Activator
Danshensu sodium, a phenolic compound, serves as an Nrf2 activator, effectively inducing the Nrf2/HO-1 signaling pathway while inhibiting NF-κB activity. It diminishes reactive oxygen species (ROS) production, enhances antioxidant defenses, and suppresses intrinsic apoptosis. Additionally, Danshensu sodium exhibits significant antiviral properties against SARS-CoV-2, with an EC50 value of 0.97 μM. This compound is valuable for researching its anti-oxidative, anti-inflammatory, and anti-apoptotic effects, holding potential implications for COVID-19, cardiovascular, and cerebrovascular diseases. -
PROTAC XPO1 Degrader
PROTAC XPO1 degrader-1 is a targeted protein degrader designed to selectively promote the degradation of XPO1. This compound demonstrates significant anti-proliferative effects, induces apoptosis, inhibits NF-κB signaling, and causes cell cycle arrest at the G1 phase. It is an important tool for researching hematological malignancies, offering insights into therapeutic strategies by modulating XPO1 levels. -
Bioactive Compound
Arjunolic acid is a multifunctional bioactive compound known for its diverse biological activities. It exhibits potent free radical scavenging properties and demonstrates significant antifungal and antibacterial effects. Arjunolic acid induces apoptosis in various cancer cell lines and offers hepatoprotection against oxidative stress by decreasing reactive oxygen species and inhibiting NF-κB activation. Its regulatory effects extend to pancreatic dysfunction in type 2 diabetic models, neuroinflammation, and Crohn's disease-like colitis, showcasing its potential in addressing conditions such as osteosarcoma and diabetic retinopathy. Research applications include studies on diabetes, organ toxicity, inflammation, and cancer progression. -
Nampt/SIRT1/PRDX5 Activator
Myricanol is a diarylheptanoid that acts as a Nampt activator, enhancing SIRT1 and PRDX5 activities. This compound exhibits notable anti-inflammatory properties and mitigates glucocorticoid-induced muscle atrophy while regulating inflammatory mediators. Additionally, it demonstrates growth inhibition and promotes apoptosis in human lung adenocarcinoma A549 cells. Myricanol is also implicated in neuroprotection via autophagy-mediated clearance of microtubule-associated protein tau and contributes to cardiovascular health by inhibiting key signaling pathways such as PDGFRβ and NF-κB. Its activation of mitochondrial transcription factor A (TFAM) further supports anti-renal fibrosis effects and improves insulin sensitivity through AMPK activation. -
JAK2/STAT3/NF-κB Inhibitor
Reticuline acts as a JAK2/STAT3 and NF-κB signaling pathway inhibitor, displaying notable anti-inflammatory properties. It effectively downregulates the mRNA expression of pro-inflammatory cytokines such as TNF-α and IL-6 while also reducing the phosphorylation levels of JAK2 and STAT3. Additionally, Reticuline demonstrates potential cardiovascular effects, making it a valuable tool for research in inflammation and cardiovascular studies. -
α7 nAchR/JAK2/STAT3 Agonist
α7 nAchR-JAK2-STAT3 agonist 1 is a selective agonist targeting the α7 nicotinic acetylcholine receptor, modulating the JAK2-STAT3 signaling pathway. It demonstrates significant anti-inflammatory activity by inhibiting the expression of inducible nitric oxide synthase (iNOS), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in murine RAW264.7 macrophages, with an IC50 of 0.32 μM for nitric oxide production. Additionally, it effectively suppresses lipopolysaccharide (LPS)-induced nitric oxide release, NF-κB activation, and related cytokine production. This compound is valuable for studying sepsis and inflammatory responses. -
JAK/STAT and NF-κB Inhibitor
JAK-IN-23 is a potent dual inhibitor of the JAK/STAT and NF-κB signaling pathways, targeting JAK1, JAK2, and JAK3 with IC50 values of 8.9 nM, 15 nM, and 46.2 nM, respectively. This compound effectively modulates the expression of interferon-stimulated genes (ISG) and inhibits NF-κB activation, exhibiting IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 demonstrates significant anti-inflammatory properties by reducing the release of various pro-inflammatory cytokines. Its applications include research into inflammatory bowel disease (IBD) and other related inflammatory conditions. -
IRAK4/IRAK1 Inhibitor
IRAK4 modulator-2 is a selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1, exhibiting IC50 values of 0.005 μM and 0.97 μM, respectively. This compound effectively disrupts IRAK-mediated signaling pathways, including JAK-STAT and NF-κB pathways, leading to a reduction in pro-inflammatory cytokine production, such as IL-1 and TNF. IRAK4 modulator-2 demonstrates potential for use in research focusing on autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. -
Cathepsin L/JAK Inhibitor
Dual Cathepsin L/JAK-IN-1 is a dual inhibitor targeting Cathepsin L (CTSL) and Janus kinases (JAK), exhibiting IC50 values of 0.68 μM for CTSL, 337.1 nM for JAK1, 5.251 nM for JAK2, 27.29 nM for JAK3, and 172.6 nM for TYK2. This compound effectively inhibits the activation of key signaling pathways, including MAPK, NF-κB, and JAK/STAT, thereby providing substantial anti-inflammatory effects. Dual Cathepsin L/JAK-IN-1 is useful for investigating mechanisms underlying acute lung injury (ALI) and other inflammatory conditions. -
IKKβ/JAK2 Inhibitor
EC-70124 is an orally active multikinase inhibitor that targets IKKβ and JAK2. By blocking IkB phosphorylation and the activation of STAT3 (Tyr705), EC-70124 inhibits NF-κB nuclear translocation and impedes STAT3 transcriptional activity. This compound has demonstrated the ability to reduce tumor growth and diminish cancer stem cell populations in prostate cancer cells and xenograft models, making it a valuable tool for research in prostate cancer. -
Anti-osteoclastic Bone Agent
FGFR1 inhibitor-11 is a selective inhibitor targeting Fibroblast Growth Factor Receptor 1 (FGFR1). It effectively disrupts downstream signaling pathways, including ERK1/2 and IκBα/NF-κB, leading to the inhibition of RANKL-induced osteoclastogenesis. This compound demonstrates oral bioactivity and is valuable in research focused on bone resorption and osteoclast development. -
Slow-releasing H2S Donor
FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. This compound inhibits NF-κB activity, leading to the induction of apoptosis in various cell types. FW1256 demonstrates significant anti-inflammatory properties and shows promise for applications in the treatment of cancer and cardiovascular diseases. -
Stable Isotope
Sodium propionate-d5, a deuterated form of sodium propionate, primarily acts as a stable isotope label in metabolic studies. This short-chain fatty acid is produced by intestinal bacteria through dietary fiber metabolism and enhances PPAR-γ, while inhibiting NF-κB activation, COX-2 expression, and nitric oxide production. Sodium propionate-d5 displays biological activities such as inducing apoptosis and autophagy, along with potential neuroprotective, antioxidant, and anti-inflammatory effects. It serves as a valuable tool for investigating conditions such as spinal cord injury, Alzheimer's disease, and glioblastoma. -
Autophagy Inducer
Sanguinarine is a benzophenanthridine alkaloid that acts as an autophagy inducer. It is derived from the root of Sanguinaria canadensis and can stimulate apoptosis through the production of reactive oxygen species (ROS). The pro-apoptotic effects of sanguinarine are linked to the activation of the JNK and NF-κB signaling pathways, making it a valuable tool for research in cancer biology and cellular stress responses. -
NF-κB Inhibitor
2′-Hydroxychalcone is a hydroxyl derivative of chalcones that primarily inhibits the NF-κB signaling pathway. It has demonstrated significant anticancer activity, inducing autophagy and apoptosis specifically in breast cancer cells. Additionally, 2′-Hydroxychalcone exhibits enhanced antifungal properties against Paracoccidioides spp., making it a valuable reagent for cancer and fungal research applications. -
Stable Isotope
Sodium propionate-d3 is a deuterium-labeled form of sodium propionate, a short-chain fatty acid that functions as a stable isotope. It selectively enhances PPAR-γ activation while inhibiting NF-κB activation, reducing COX-2 expression and nitric oxide production. This compound exhibits significant biological activities, including apoptosis induction and autophagy promotion, along with neuroprotective, antioxidant, and anti-inflammatory properties. Sodium propionate-d3 is valuable in research applications related to spinal cord injury, Alzheimer's disease, and the treatment of glioblastoma, as well as in studying viral infections such as HSV-1-induced keratitis. -
NF-κB Inhibitor/Nrf2/AMPK Activator
Panduratin A is a potent inhibitor of the NF-κB signaling pathway, recognized for its significant anti-inflammatory and antioxidant properties. It demonstrates protective effects against nephrotoxicity induced by Colistin, primarily by mitigating oxidative stress and enhancing mitochondrial function. Additionally, Panduratin A activates autophagy through an AMPK-dependent mechanism and exhibits potential anti-tuberculosis and antiviral activities by inhibiting the methyltransferase of SARS-CoV-2. These diverse biological activities make Panduratin A a valuable tool in various areas of research, including inflammation, cellular stress responses, and infectious diseases. -
Stable Isotope
Laquinimod-d5 is a deuterium-labeled variant of Laquinimod, a potent immunomodulator primarily targeting neuroinflammation in the central nervous system. This compound effectively reduces astrocytic NF-κB activation, offering protection against demyelination induced by Cuprizone. Laquinimod-d5 is intended for research applications exploring relapsing-remitting and chronic progressive forms of multiple sclerosis, as well as various neurodegenerative diseases. -
Molecular probe
AMC-01 is a molecular probe that specifically regulates the activity of eIF2-α. It induces the activation of protein kinase RNA-activated (PKR) and enhances nuclear factor κB (NF-κB) signaling. Additionally, AMC-01 functions to inhibit apoptosis, making it a valuable tool for investigating cellular stress responses and signaling pathways in various research applications. -
Anticancer Agent
(-)-Hinesol primarily functions as a potent anticancer agent. It induces apoptosis and causes cell cycle arrest at the G0/G1 phase. This compound downregulates the MEK/ERK and NF-κB signaling pathways, influencing the expression of key proteins such as cyclin D1, Bax, and Bcl-2. (-)-Hinesol shows significant potential for the research of non-small cell lung cancer. -
IRAK4 Inhibitor
Emavusertib hydrochloride is an orally active inhibitor targeting IRAK4, with an IC50 of 57 nM, and FLT3. This compound effectively inhibits NF-κB and MyD88 signaling pathways, resulting in decreased production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, as it promotes apoptosis in cancer cells and demonstrates antitumor efficacy in mouse model studies. -
Immunomodulator
Laquinimod sodium is a potent immunomodulator targeting neuroinflammation and neurodegeneration within the central nervous system. This orally available carboxamide derivative effectively reduces astrocytic NF-κB activation, offering protection against Cuprizone-induced demyelination. Laquinimod sodium is applicable in research focused on relapsing-remitting and chronic progressive forms of multiple sclerosis, as well as in studies of various neurodegenerative diseases. -
Cereblon Modulator
Avadomide hydrochloride is an oral cereblon modulator that targets cereblon E3 ligase activity. By inhibiting the NF-κB signaling pathway and arresting the cell cycle at the G1 phase, it effectively induces apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. This compound demonstrates significant antitumor and immunomodulatory properties, making it a valuable reagent for cancer research applications. -
Apoptosis Inducer
Apoptosis Inducer 46 targets apoptotic pathways to induce cell death selectively in metastatic triple-negative breast cancer (TNBC) cells. It demonstrates potent growth inhibitory effects, specifically causing G2/M phase cell cycle arrest and promoting apoptotic cell death in MDA-MB-231 cells. Additionally, Apoptosis Inducer 46 inhibits NF-κB nuclear translocation, highlighting its potential for research applications in the study of TNBC. -
Antioxidant
Astaxanthin is a potent antioxidant primarily targeting NF-κB, leading to the down-regulation of VEGF in blood glucose regulation. This carotenoid exhibits significant anti-cancer properties by inhibiting cell proliferation, enhancing apoptosis, and preventing migration and invasion through PPARγ activation and STAT3 expression reduction. Additionally, astaxanthin demonstrates neuroprotective and anti-inflammatory activities, making it applicable in various research fields, including cancer, diabetic retinopathy, and cardiovascular disease, as well as in the enhancement of animal feed coloration. -
Short-chain Fatty Acid
Sodium propionate is a short-chain fatty acid with multiple biological activities, primarily functioning as an oral bioactive compound. It enhances PPAR-γ activity while inhibiting NF-κB activation, leading to reduced COX-2 expression and nitric oxide production. Additionally, sodium propionate has demonstrated the ability to induce apoptosis and autophagy, exhibit anticancer effects against glioblastoma, and provide neuroprotective, antioxidant, and anti-inflammatory properties. This compound is suitable for research applications in areas such as spinal cord injury and Alzheimer's disease. -
TLR7/8 Antagonist
Afimetoran is a selective and highly bioavailable antagonist of Toll-like receptors 7 and 8 (TLR7/8). It effectively inhibits TLR7/8-mediated activation of the NF-κB signaling pathway and can reverse TLR7-induced resistance to steroid-driven apoptosis in plasmacytoid dendritic cells. This compound is particularly relevant for research into inflammation and autoimmune diseases, including systemic lupus erythematosus. -
Vascular Function Regulator
12-HETE is a significant metabolite of arachidonic acid produced via 12-lipoxygenase (12-LOX) catalysis, functioning as a vascular function regulator. It exhibits dose-dependent inhibition of cell apoptosis and promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway. Additionally, 12-HETE has been shown to possess both anti-thrombotic and pro-thrombotic effects, as well as neuromodulatory properties, making it valuable for research in vascular biology and related therapeutic areas. -
TRIP13 Inhibitor
DCZ0415 is a potent inhibitor of TRIP13, interfering with the nonhomologous end joining DNA repair mechanism and inhibiting NF-κB activity. This compound exhibits significant anti-myeloma activity in vitro, in vivo, and in primary cells obtained from drug-resistant myeloma patients, making it a valuable tool for research into therapeutic strategies against multiple myeloma. Its mechanism of action offers insights into the role of TRIP13 in cancer biology and the potential for targeted therapies. -
TLR2/4 Inhibitor
Robinin is a flavonoid that acts as an inhibitor of Toll-like receptors 2 and 4 (TLR2/4), modulating the TGF-β, TLR4/NF-κB, and TLR2-PI3k-AKT signaling pathways. This compound demonstrates significant anti-inflammatory and anti-tumor properties. Additionally, Robinin has been shown to enhance the anti-inflammatory effects of Methotrexate in experimental arthritis models and may mitigate cardiac toxicity induced by Doxorubicin. These attributes make Robinin a valuable reagent for research applications in inflammation and cancer therapy. -
Mucolytic Agent
Carbocisteine is an orally active mucolytic agent primarily targeting the modulation of mucous viscosity in respiratory conditions. It inhibits the phosphorylation of NF-κB p65 and ERK1/2, and further regulates the interplay between Nrf2/HO-1 and NF-κB pathways. Additionally, carbocisteine has demonstrated anti-apoptotic properties. This reagent is primarily utilized in research related to chronic obstructive pulmonary disease (COPD). -
ACE/IKK-β/PKC Inhibitor
Plantainoside D is a phenylethanoid glycoside that functions primarily as an inhibitor of IKK-β, with additional inhibitory effects on angiotensin-converting enzyme (ACE) and protein kinase C (PKC). It exhibits significant biological activities, including the reduction of glutamate release in the rat cerebral cortex, alleviating cell apoptosis through the inhibition of reactive oxygen species (ROS) and NF-κB activation. Additionally, Plantainoside D has been shown to improve outcomes in acute lung injury induced by sepsis via modulation of the Sirt3/NLRP3 signaling pathway. This compound is applicable in studies of neuroprotection, antioxidant activity, anti-inflammatory responses, and antihypertensive effects. -
TREM-1 Inhibitor
Nangibotide is a synthetic peptide that serves as a TREM-1 receptor inhibitor. By inhibiting NF-κB and NLRP3 inflammasome activation, Nangibotide effectively reduces the release of pro-inflammatory cytokines such as IL-1β and IL-8 and mitigates apoptosis. This reagent is valuable for research applications related to excessive inflammatory responses, including studies on myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure. Additionally, Nangibotide offers protective effects on tissues, such as the liver and lung, during inflammatory conditions. -
Bioactive Peptide
MOTS-c (human) is a bioactive peptide derived from mitochondria that modulates the AMPK/PGC-1α pathway, thereby enhancing insulin sensitivity. This peptide inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, which regulates the Nrf2/Keap1 antioxidant pathway and suppresses the NF-κB inflammatory pathway. MOTS-c promotes mitochondrial biogenesis and energy metabolism, resulting in improvements in glucose and lipid metabolism, anti-oxidative stress, and neuroprotection. It is applicable in research studying type 2 diabetes, traumatic brain injury, inflammatory diseases, and age-related metabolic disorders. -
Prolyl-hydroxylase Inhibitor
Ethyl 3,4-dihydroxybenzoate is a competitive inhibitor of prolyl hydroxylase, effectively penetrating the blood-brain barrier. By inhibiting the hydroxylation of hypoxia-inducible factor (HIF), it stabilizes HIF-1α, thereby activating downstream pathways that promote autophagy and apoptosis in tumor cells. Additionally, it modulates inflammatory responses, inhibits the NF-κB pathway, enhances vascular permeability, and supports osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate is beneficial for research applications focused on cancer therapeutics, cardiovascular protection, bone metabolism regulation, and high-altitude cerebral edema management. -
Keap1-Nrf2 Protein-Protein Inhibitor
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting an IC50 of 0.63 µM. This compound demonstrates significant anti-inflammatory and antioxidant properties by activating the Nrf2-dependent pathway and inhibiting the NF-κB-related inflammatory response. CPUY192018 is ideal for research applications focused on inflammation-related diseases and the modulation of oxidative stress. -
Anticancer/Antiparasitic Agents
Bruceine A, a natural quassinoid, primarily targets NF-κB and PFKFB4, demonstrating a Kd of 44 nM. This compound exhibits potent anticancer and antiparasitic activities, effectively inhibiting cancer cell migration and inducing apoptosis while also disrupting the cell cycle. Bruceine A is a valuable research tool for studying pancreatic cancer, breast cancer, and parasitic infections. -
Anti-inflammatory agent
Hederacoside C is a potent anti-inflammatory agent that targets the MAPK/NF-κB signaling pathway. It exerts its biological activity by inhibiting the activation of this pathway, resulting in a reduction of inflammation. In addition to its anti-inflammatory properties, Hederacoside C also demonstrates antibacterial activity, making it a valuable compound for research applications focused on inflammatory diseases and infections. -
Drug Derivative
(+)–Rocaglamide is a selective inhibitor of heat shock factor 1 (HSF1), exhibiting an IC50 value of 50 nM. It is effective in inhibiting NF-κB activation in T-cells and the activity of the translation initiation factor eIF4A. Research applications include its potential use in anti-inflammatory treatments and as an anticancer agent, particularly against leukemia. This compound is derived from the genus Aglaia and demonstrates promising therapeutic properties for various conditions, including inflammatory diseases. -
GADD45β/MKK7 Inhibitor
DTP3 TFA is a highly selective inhibitor of GADD45β/MKK7, targeting a critical pathway involved in cell survival in cancer cells downstream of the NF-κB signaling cascade. This compound exert biological activity by disrupting the function of the GADD45β/MKK7 module, influencing cellular responses to DNA damage and stress. DTP3 TFA serves as a valuable tool in cancer research, particularly in studies investigating the mechanisms of cell survival and the potential for therapeutic interventions in malignancies associated with aberrant NF-κB activity. -
Anti-Inflammatory Agent
Vitisin A is a resveratrol tetramer with potent anti-inflammatory properties. It exerts its biological activity by inhibiting LPS-induced nitric oxide (NO) and inducible nitric oxide synthase (iNOS) production through the down-regulation of ERK1/2, p38, and NF-κB signaling pathways. Additionally, Vitisin A demonstrates antioxidative, anticancer, and neuroprotective effects while also inhibiting adipocyte differentiation. This compound is derived from the roots of Vitis vinifera and serves as a valuable reagent for research in inflammation and related diseases. -
Inflammation Inhibitor
Resolvin D5 is an anti-inflammatory agent primarily targeting the GPR32 receptor, effectively modulating inflammation responses. It alleviates Paclitaxel-induced mechanical allodynia and inflammatory pain in male mice through mechanisms that do not involve TRPV1 or TRPA1 channels. Resolvin D5 reduces LPS-induced ERK phosphorylation and NF-κB nuclear translocation while downregulating pro-inflammatory mediators, inhibiting Th17 differentiation, and promoting regulatory T cell differentiation. This compound is particularly relevant for research on chemotherapy-induced peripheral neuropathy, inflammatory pain, and rheumatoid arthritis. -
NF-κB&ERK1/2 Inhibitor
OP-1118 is a potent dual inhibitor of NF-κB and ERK1/2, targeting critical signaling pathways involved in inflammation and cell survival. This compound demonstrates significant anti-inflammatory, cytoprotective, anti-apoptotic, and antibacterial activities by inhibiting the phosphorylation of NF-κB and ERK1/2, leading to a reduction in pro-inflammatory cytokine expression. In preclinical models of Clostridium difficile infection, OP-1118 effectively mitigates toxin-induced intestinal inflammation, cellular damage, and apoptosis, with its protective effects possibly reversible by PMA. This makes OP-1118 a valuable reagent for research into inflammatory conditions and therapeutic interventions. -
Anti-inflammatory Agent
24-O-Acetyllycoclavanol is a triterpenoid compound that functions as an anti-inflammatory agent by selectively targeting the NF-κB and ERK1/2 signaling pathways. Its biological activity includes the inhibition of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to decreased production of inflammatory mediators like nitric oxide (NO), IL-1β, and IL-8. This compound is particularly relevant for research applications in the context of inflammatory bowel disease (IBD) and can be isolated from the ethyl acetate extract of Lycopodium clavatum. -
Anti-inflammatory Agent
Anti-inflammatory agent 31 is a derivative of andrographolide that functions primarily by inhibiting NF-κB activation through the upstream blockade of the PI3K/Akt and ERK1/2 MAPK signaling pathways. This compound exhibits notable anti-inflammatory activity, promoting the recovery of intracellular glutathione (GSH) levels. Additionally, anti-inflammatory agent 31 demonstrates a protective effect on liver cells, making it a valuable tool for research applications in inflammation and hepatoprotection. -
Antioxidant/Anti-inflammatory/Anticancer Agent
Licoflavanone, a flavanone with antioxidant, anti-inflammatory, and anticancer properties, is isolated from the leaf extract of Glycyrrhiza glabra. It exerts its anticancer effects by downregulating the mTOR/PI3K/AKT signaling pathway, leading to inhibition of cancer cell proliferation, migration, and invasion. Additionally, Licoflavanone activates pro-apoptotic factors such as Bax and Bad, along with multiple caspase enzymes. Its anti-inflammatory activity involves reducing NF-κB nuclear translocation and decreasing the phosphorylation of p38, JNK, and ERK1/2, ultimately inhibiting pro-inflammatory cytokines, COX-2, and iNOS expression. This compound is utilized in research on nasopharyngeal carcinoma and its underlying mechanisms. -
CK1α Degrader
INNO-220 is a CRBN-dependent molecular glue degrader that specifically targets CK1α. This orally active compound induces cell cycle arrest at the G0/G1 phase and promotes apoptosis through the degradation of CK1α. Additionally, INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, effectively inhibiting NF-κB signaling in stimulated T cells and lymphoma cells with activating mutations in CARD11. This reagent serves as a valuable tool for advancing research in lymphoma. -
TMA /TMAO Inhinbitor
3,3-Dimethyl-1-butanol is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO), acting via the suppression of the p65 NF-κB signaling pathway and the TGF-β1/Smad3 pathway. This compound exhibits significant potential in the study of cardiovascular diseases (CVD), making it a valuable reagent for researchers investigating the molecular mechanisms underlying these conditions.
